Long-term venous thromboembolism (VTE) recurrences and bleedings according to cancer site: Data from the RIETE registry.

e22226 Background: the venous thromboembolism (VTE) events, in cancer patients, are treated with low-molecular-weight heparin (LMWH) for a period of 3-6 months in according to international guidelines. The benefits of a treatment option beyond 6 months of LMWH administration is not clearly defined. Long- term anticoagulation is most often suggested because of the persisting risk of recurrent VTE but data are very sparse and comprise all types of cancer.To assess according to the type of cancer the rate of recurrent VTE, major bleeding and death at 12 months in patients who experienced VTE in a context of active cancer and receiving anticoagulation for at least 3 months. Methods: We used data from Registro Informatizado de Enfermedad TromboEmbolica (RIETE) registry, an ongoing international, multicentred, real-life prospective registry of consecutive patients presenting with symptomatic, acute VTE. All patients provided written or oral consent for participation in the registry. Outcome measures included sy...